<\/p>\n
I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO’s job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in.<\/p>\n
And Novo Nordisk CEO Mike Doustdar is honestly trying that with one specific data point.<\/p>\n
The 102-year-old Danish pharmaceutical giant reported Q2 2026 results on Aug. 4 and raised its full-year guidance. But the number that mattered most was not in the financials. It was in the prescription trajectory of the Wegovy pill.\u00a0<\/p>\n
The first million prescriptions took 11 weeks, with no competitor in the market. The most recent million prescriptions took four weeks, with a competitor actively fighting for market share.<\/p>\n
“We have not allowed that,” Doustdar told CNBC’s Carolin Roth.<\/p>\n
Currently, Novo Nordisk (NVO) is down 9.87% year to date, according to Yahoo Finance.<\/p>\n
Also Read: Novo Nordisk Latest News and Stories<\/p>\n
What the Novo Nordisk Wegovy data actually reveal<\/p>\n
Five million total prescriptions have been written for the Wegovy pill since its U.S. launch, according to an Aug. 4 CNBC interview. Weekly prescriptions exceeded 265,000 for the week ending July 17, according to the company’s Q2 earnings release.<\/p>\n
The acceleration narrative is the argument Novo Nordisk is making to investors who have been skeptical about GLP-1 adoption. Prescription velocity is increasing, not slowing, as the product matures in the market and faces competition.<\/p>\n
More Novo Nordisk:<\/p>\n
Novo Nordisk shares in hot water after disappointing trialOzempic maker takes biggest rival to court over weight-loss drug adsNovo and Lilly shift GLP-1 strategy abroad: US may be next<\/p>\n
Here is something vital. The user demographics add another dimension that the quarterly print does not fully capture. Approximately 80% of patients starting the Wegovy pill have never taken a GLP-1 treatment before, according to Doustdar in the CNBC interview.\u00a0<\/p>\n
This is predominantly new-patient volume, not cannibalization of existing Wegovy injectable users. The cannibalization occurring \u2014 the 20% who switch \u2014 is coming primarily from competitors’ products, rather than from Novo’s own franchise.<\/p>\n
That profile is strategically important. If the pill is capturing GLP-1 naive patients, it is expanding the total addressable market rather than redistributing it internally.<\/p>\n
Novo Nordisk Q2 2026 financial results: adjusted vs. reported growth<\/p>\n
Novo Nordisk’s Q2 results require some careful reading. Why? Because of a significant prior-year comparison distortion, according to the company’s Aug. 4 earnings release.<\/p>\n
Q2 2026 reported sales increased by just 3% at constant exchange rates (CER), negatively impacted by a DKK 2.6 billion rebate provision reversal related to the U.S. 340B Drug Pricing Program, which had boosted Q2 2025 results.Adjusted sales grew 7% at CER, driven by GLP-1 volume growth across geographies and favorable U.S. rebate adjustments.Adjusted operating profit grew 11% at CER.\u00a0Reported operating profit declined 16% at CER, impacted by non-cash impairment charges of DKK 6.3 billion related to intangible pipeline assets, including DKK 4.0 billion tied to the monlunabant program.<\/p>\n
Its guidance raise is the headline you should also note. Novo raised its full-year 2026 guidance for adjusted sales growth and adjusted operating profit growth.\u00a0<\/p>\n
The improved outlook is driven by increased expectations for GLP-1 product sales, with Wegovy pill adoption in the U.S. and international market expansion as the primary drivers.<\/p>\n
Novo Nordisk launched the Wegovy pill in the UAE in June, achieving 50% market share within three weeks, despite entering as the second competitor.<\/p>\n
Michael Siluk/UCG/Universal Images Group via Getty Images<\/p>\n
International expansion and the pipeline behind the domestic story<\/p>\n
Beyond the U.S. numbers, Novo is building a global Wegovy pill rollout that gives the prescription trajectory a multi-year tailwind.<\/p>\n
The company launched the Wegovy pill in the UAE in June, achieving 50% market share within three weeks, despite entering as the second competitor, according to Doustdar’s interview and the Q2 earnings report.<\/p>\n
The U.K. reached 300,000 active patients. Meanwhile, the European Medicines Agency approved the Wegovy pill in July based on the OASIS 4 trial, which demonstrated up to 16.6% weight loss mean. <\/p>\n
Related: Goldman Sachs doubles down on Novo stock target after key event<\/p>\n
Germany is among the first European markets planned for the drug’s rollout.<\/p>\n
Separately, the Wegovy 7.2 mg single-dose pen, which provides up to 20.7% mean weight loss based on STEP UP trial data, received EMA approval in July and launched in the U.S. in April. That higher-dose formulation extends the product ladder within the Wegovy franchise.<\/p>\n
One pipeline setback in Q2 is that the ZEUS Phase 3 trial with ziltivekimab in cardiovascular disease did not meet its primary endpoint, Cardiology Advisor reported. That result contributed to the DKK 4 billion impairment charge in Q2.<\/p>\n
What Doustdar’s confidence means for NVO, which has delivered years of gains<\/p>\n
Here’s my read of the CEO’s CNBC performance: The pill is accelerating in a competitive market, the majority of users are new to GLP-1 therapy, and the guidance raise reflects genuine operational momentum rather than financial engineering.<\/p>\n
The stock trading 38% down over three years shows that the market’s skepticism has been deep.\u00a0<\/p>\n
The question heading into the second half of 2026 is whether the prescription acceleration Doustdar described sustains into Q3, European launches begin contributing meaningful revenue, and the 80% new-patient capture rate holds.<\/p>\n
“Raising guidance is why I’m bullish,” Doustdar said on CNBC. “It’s about making a promise to your stakeholders and over-delivering.” The prescription data he cited on Aug. 4 is his evidence that the promise is tracking.\u00a0<\/p>\n
Related: Wall Street sees huge upside as Novo Nordisk backs biotech company<\/p>\n
#Novo #Nordisk #CEO #resets #expectations #Wegovy039s #explosive #growth<\/p>\n","protected":false},"excerpt":{"rendered":"
I believe that when a stock is down nearly 10% year to date and down…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[585,651,14081,1737,8525,5742,1307,18848],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13020"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13020"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13020\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}